United Therapeutics Corporation reports results for the quarter ended June 30 - Earnings Summary

United Therapeutics

05/08/2026 13:11

United Therapeutics Corporation UTHR.OQ reported quarterly adjusted earnings of $7.27​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $6.41.  The mean expectation of twelve analysts for the quarter was for earnings of $6.83 per share. Wall Street expected results to range from $6.07  to $7.76 per share.
Revenue fell 1.9% to $783.30 million from a year ago; analysts expected $805.65 million. 
United Therapeutics Corporation's reported EPS for the quarter was $7.27​.
The company reported quarterly net income of $333 million.
United Therapeutics Corporation shares had fallen by 4.3% this quarter and gained 6.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 3.3% in the last three months.​ 
In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for United Therapeutics Corporation is $695.00, about 25.4% above its last closing price of $518.68
This summary was machine generated from LSEG data August 5 at 12:11 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
6.83
7.27
Beat
Mar. 31 2026 
6.87
5.82
Missed
Dec. 31 2025 
7.19
7.70
Beat
Sep. 30 2025 
7.19
7.16
Missed